Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Japan”
- Nipocalimab in Moderate to Severe Sjogren's DiseaseActive Not Recruiting
Sponsor: Janssen Research & Development, LLC
Sjogrens Syndrome
United States, Argentina, Austria, Brazil, Bulgaria +23 more
- A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Active Not Recruiting
Sponsor: Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, Chronic, B-Cell
United States, Australia, China, Denmark, France +3 more
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling By Invitation
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Australia, Brazil, Chile, China +12 more
Sponsor: Astellas Pharma Inc
Solid Tumor
United States, China, France, Japan, Puerto Rico +2 more
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active Not Recruiting
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +21 more
Sponsor: Janssen Research & Development, LLC
Dermatitis, Atopic
United States, Argentina, Brazil, Canada, Germany +4 more
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruiting
Sponsor: Astellas Pharma Global Development, Inc.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or Cancer · Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
United States, Australia, Belgium, Brazil, Chile +17 more
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Australia, Canada, China, France +9 more
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive Not Recruiting
Sponsor: Eli Lilly and Company
Atopic Dermatitis · Eczema
United States, Argentina, Australia, Brazil, Canada +7 more
Sponsor: Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
United States, Australia, Belgium, Brazil, Canada +12 more
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisActive Not Recruiting
Sponsor: Janssen Pharmaceutical K.K.
Generalized Pustular Psoriasis · Erythrodermic Psoriasis
Japan
Sponsor: Chugai Pharmaceutical
Locally Advanced or Metastatic Solid Tumors
United States, Japan
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active Not Recruiting
Sponsor: AstraZeneca
Breast Cancer; HER2-positive; Metastatic
United States, Argentina, Belgium, Brazil, Canada +22 more
Sponsor: Eli Lilly and Company
Diabetic Peripheral Neuropathy
United States, Czechia, Japan, Poland, South Korea
Sponsor: Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
United States, Argentina, Australia, Austria, Belgium +34 more
Sponsor: GlaxoSmithKline
Respiratory Syncytial Virus Infections
United States, Australia, Canada, Germany, Italy +3 more
- Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive Not Recruiting
Sponsor: AbbVie
Menstrual Migraine (MM)
United States, China, Czechia, Germany, Hungary +8 more
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling By Invitation
Sponsor: Eli Lilly and Company
Atopic Dermatitis · Eczema
United States, Argentina, Australia, Brazil, Canada +8 more
- REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active Not Recruiting
Sponsor: Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
United States, Belgium, Brazil, Bulgaria, Canada +18 more
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer
United States, Czechia, Denmark, France, Germany +5 more
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Primary IgA Nephropathy
United States, Argentina, Australia, Belgium, Brazil +30 more
Sponsor: Bristol-Myers Squibb
Solid Tumors
United States, Belgium, Canada, China, France +8 more
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisActive Not Recruiting
Sponsor: AstraZeneca
Eosinophilic Esophagitis
United States, Australia, Austria, Belgium, Brazil +17 more
Sponsor: Regeneron Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Canada, Colombia, Hungary, India, Italy +14 more
Sponsor: Amgen
KRAS Altered Advanced or Metastatic Solid Tumors
United States, Australia, Belgium, Canada, China +9 more